The phase III MATTERHORN trial showed treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response versus neoadjuvant chemotherapy alone for patients with resectable, early-stage and locally advanced (stages 2, 3, 4A) gastric and gastroesophageal junction cancers.
Perioperative treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival versus chemotherapy alone, according to MATTERHORN phase III trial results.
